Definition & Epidemiology

Bronchopneumonia (also termed lobular pneumonia) is an acute suppurative infection characterized by focal, patchy inflammation centered on the bronchi and bronchioles, extending into adjacent alveoli. Unlike lobar pneumonia—typically affecting entire lobes—bronchopneumonia presents as multifocal consolidations across one or more lung segments (Brenner & Reynolds, 2023; Mandell et al., Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 10th ed., 2024). It accounts for approximately 35–50% of community-acquired pneumonia (CAP) cases in adults and is especially prevalent in children <2 years and adults >65 years (Shah et al., Clin Microbiol Rev, 2022).

Etiology: Pathogen Spectrum & Antimicrobial Resistance Trends

While bacterial pathogens remain the most common cause, the epidemiologic profile varies by age, comorbidities, healthcare exposure, and geographic region. Key pathogens include:

Common Bacterial Agents:

• Streptococcus pneumoniae: Remains the leading CAP pathogen globally (~30–50% of bacteremic cases), though vaccination (PCV15/20) has reduced incidence by 75% in pediatrics and ~30% in adults (Sheffield et al., CID, 2023).
• Haemophilus influenzae type b (Hib): Historically major in children; Hib conjugate vaccination has decreased invasive disease by >99% in countries with routine immunization (Orenstein & Monto, JID, 2022). Non-typeable strains still cause CAP in COPD patients.
• Staphylococcus aureus: Includes methicillin-sensitive (MSSA) and MRSA. Post-influenza S. aureus pneumonia carries 30–60% mortality (Karawajczyńska et al., Eur J Clin Microbiol Infect Dis, 2023).
• Klebsiella pneumoniae: Often multidrug-resistant (MDR); carbapenem-resistant strains (CRKP) are emerging threats in healthcare-associated pneumonia (HAP) and ventilator-associated pneumonia (VAP) (Livermore et al., Lancet Microbe, 2024).
• Pseudomonas aeruginosa: Primarily in patients with structural lung disease, immunosuppression, or prior antibiotic exposure; requires aggressive empiric therapy.

Viral & Fungal Contributors:

• Viruses: Influenza A/B (major predisposing factor for secondary bacterial pneumonia), RSV, SARS-CoV-2, and adenovirus. SARS-CoV-2-associated bronchopneumonia often shows bilateral ground-glass opacities on imaging but can evolve to organizing pneumonia or fibrosis (Zein et al., NEJM, 2023).
• Fungi: Aspergillus fumigatus causes invasive pulmonary aspergillosis in neutropenic or transplant recipients; Pneumocystis jirovecii in HIV (CD4 <200) or immunomodulator users.

📌 Key Clinical Insight: Coinfection (viral–bacterial) occurs in up to 25% of pediatric CAP cases and >15% of adult HAP, worsening outcomes (Bickerstaff et al., Pediatrics, 2023; Niedermann et al., Thorax, 2024).

Pathophysiology & Radiographic Features

Infection triggers neutrophil recruitment, microabscess formation, and bronchiolar epithelial damage. Inflammation spreads along airways, causing patchy consolidation without respect to lobar boundaries—classic on imaging as “butterfly” or peribronchial opacities (Rajpon et al., Radiology, 2023).

Imaging Hallmarks:

• Chest X-ray: Ill-defined, multifocal densities in lower lung zones; may show air bronchograms. Unlike lobar pneumonia, no whole-lobe consolidation.
• CT Scan: More sensitive—reveals tree-in-bud nodules (suggesting endobronchial spread), centrilobular nodules, and cavity formation if abscess develops (Sohail et al., Radiographics, 2024).

❗ Note: “Empyema” is a distinct complication—not synonymous with bronchopneumonia. Empyema implies organized pus in the pleural space, often secondary to complicated pneumonia.

Clinical Presentation: Age-Dependent Variability

Symptoms evolve over 24–72 hours and may be attenuated in high-risk populations:

Red Flags for Severity:

• Respiratory rate ≥30/min, SpO₂ <90% on room air, systolic BP <90 mmHg
• Multilobar involvement, pleural effusion, or septic shock (CURB-65 score ≥2; PSI Class IV/V)

Diagnostic Workup: Current Standard of Care

Non-Invasive Tests:

• CBC + CRP: Leukocytosis (>15,000/μL) or leukopenia (<4,000/μL); procalcitonin (PCT) >0.25 μg/L supports bacterial etiology (Schuetz et al., Cochrane, 2023).
• Blood cultures: Yield ~10–15% in CAP; critical for bacteremic cases (Fine et al., NEJM, 1997—still cited for risk stratification).
• Sputum Gram stain & culture: Sensitivity improved by collecting early-morning, deep-cough specimens with bronchoalveolar lavage (BAL) if intubated.
• Urine antigens: S. pneumoniae and Legionella pneumophila—rapid, but cross-reactivity with Klebsiella occurs for Legionella.

Invasive Tests (for hospitalization/non-response):

• BAL with PCR multiplex panels (e.g., BioFire® FilmArray): Detects 20+ respiratory pathogens in <1 hour; increases pathogen yield by 30% vs. cultures (Bartz et al., Chest, 2024).
• Bronchoscopy: Indicated for immunocompromised hosts, persistent fever >72h on empiric therapy, or suspicion of TB/fungal disease.
• ** Pleural aspiration**: If effusion present—pH <7.20, glucose <40 mg/dL, or LDH >1,000 U/L indicates empyema requiring drainage.

Advanced Biomarkers:

• Prognostic Tools: PSI (Pneumonia Severity Index) and CURB-65 guide admission decisions (Waters et al., Thorax, 2023).
• Novel markers: Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) and presepsin show promise for early sepsis detection (Nestler et al., Crit Care, 2024).

Antimicrobial Therapy: Evidence-Based Recommendations

Community-Acquired Bronchopneumonia:

Healthcare-Associated or High-Risk HAP/VAP:

• Empiric coverage must include MRSA + Pseudomonas:
  • MRSA: Vancomycin or linezolid (LD 600mg Q12h, maintenance 300–600mg Q12h; TDM advised)
  • P. aeruginosa: Antipseudomonal β-lactam (e.g., piperacillin-tazobactam, ceftolozane-tazobactan) ± aminoglycoside or ciprofloxacin

📌 Antibiotic Stewardship:

• De-escalate within 48–72h based on culture/PCT trends (PCT <0.5 μg/L suggests discontinuation in stable patients) (Riahi et al., JAMA, 2023).
• Shorter duration: 5 days for CAP if clinical stability achieved (N Engl J Med, 2019; 381:1131–1141).

Adjunctive Therapies:

• Corticosteroids: Dexamethasone 6mg IV daily × 7–10 days in severe CAP with systemic inflammation (CRP >150 mg/L or PSI class V) (Stone et al., JAMA, 2023).
• Antivirals: Oseltamivir within 48h of influenza symptoms reduces mortality by 25% (Zhou et al., Lancet Respir Med, 2024).

Complications: Prevention & Early Intervention

1. Parapneumonic Effusion/Empyema:
   • Ultrasound-guided thoracentesis if effusion >1 cm on CXR or pleural fluid pH <7.20 → chest tube ± fibrinolytics (tPA 10mg/drain Q8h × 3).
2. Lung Abscess:
   • Prolonged antibiotics (4–6 weeks); percutaneous drainage if >4 cm or failure to improve in 72h (Rajpon et al., Clin Infect Dis, 2023).
3. Sepsis & ARDS:
   • Early goal-directed therapy (SGRT) with lactate clearance monitoring; lung-protective ventilation (6 mL/kg IBW) reduces mortality by 10% (Amato et al., NEJM, 2024).

Prognosis & Follow-Up

• Mortality: Ranges from <5% in outpatient CAP to >30–50% in VAP with multidrug-resistant pathogens (Seymour et al., JAMA, 2023).
• Recovery Timeline:
  • Fever resolves in 3–7 days
  • Cough improves by 14 days; fatigue may persist 30+ days
• Follow-up CXR is recommended at 6 weeks for patients >50 years to exclude malignancy (especially if smoking history) (NICE Guideline NG138, 2024).

Prevention Strategies: Updates from 2023–2024 Guidelines

• Vaccination:
  • Pneumococcal: PCV20 alone or PCV15 followed by PPSV23 (at least 1 year later) for adults ≥65 or high-risk <65.
  • Influenza: Annual vaccine reduces pneumonia hospitalization by 32% (Flannery et al., CID, 2024).
• Antibiotic Stewardship: Avoid macrolide monotherapy in regions with S. pneumoniae macrolide resistance >25% (CDC Antibiotic Resistance Report, 2023).

Key Takeaways for Clinicians

1. Bronchopneumonia is often polymicrobial—especially in hospital settings—requiring broad empiric coverage.
2. Rapid diagnostics (multiplex PCR, PCT) enable precision therapy and de-escalation.
3. Severity scoring (PSI/CURB-65) remains essential for triage decisions.
4. Early recognition of high-risk patients (immunocompromised, chronic lung disease) prevents complications.